Walformin Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily reduces hepatic glucose production and increases peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The synergistic action of these two agents effectively lowers blood glucose levels in patients inadequately controlled by diet and exercise alone. Walformin is typically prescribed as part of a comprehensive diabetes management plan, including diet modification, physical activity, and regular monitoring of blood glucose levels. It is contraindicated in patients with severe renal or hepatic impairment, diabetic ketoacidosis, or known hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Regular monitoring of renal function and blood glucose is recommended to minimize the risk of lactic acidosis and hypoglycemia. Walformin should be used under medical supervision with appropriate dose adjustments based on therapeutic response and patient tolerance.